Key terms
About TRVI
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization Haduvio to treat serious neurologically mediated conditions. It includes treatment of chronic pruritus associated with prurigo nodularis and chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson’s disease. The company was founded by Thomas R. Sciascia and Jennifer L. Good in March 2011 and is headquartered in New Haven, CT.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest TRVI news
Mar 24 9:30pm ET Analysts Offer Insights on Healthcare Companies: Trevi Therapeutics (TRVI), Oculis Holding (OCS) and Quanterix (QTRX) by TipRanks Mar 22 8:05am ET Buy Rating for Trevi Therapeutics Anchored on Haduvio’s Clinical Promise and Market Potential by TipRanks Mar 21 7:50am ET Analysts’ Opinions Are Mixed on These Healthcare Stocks: Vor Biopharma (VOR), Roche Holding AG (OtherRHHVF) and Trevi Therapeutics (TRVI) by TipRanks Mar 21 7:27am ET Trevi Therapeutics (TRVI) Receives a Buy from Stifel Nicolaus by TipRanks Mar 21 6:10am ET Analysts’ Top Healthcare Picks: Trevi Therapeutics (TRVI), Walgreens Boots Alliance (WBA) by TipRanks Mar 20 4:07pm ET Trevi Therapeutics reports Q4 EPS (8c), consensus (9c) by TipRanks Feb 22 10:59am ET Biotech Alert: Searches spiking for these stocks today by TipRanks
No recent news articles are available for TRVI
TRVI Financials
Ad Feedback
TRVI Forecasts
analyst rating
- buy
- hold
- sell
We're sorry, but this
information is
temporarily unavailable.
1-year stock price forecast
TRVI Competitors
$ Market cap P/E ratio $ Price 1d change 52-week range
